Atlas Trials

Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer

Clinical trial NCT07235930 · RECRUITING

Trial details

NCT number
NCT07235930
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Non-Resectable Pancreas Carcinoma
Start date
2025-11-15
Primary completion
2029-07-01
Enrollment
292

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.